Golimumab is usually a human monoclonal antibody administered after per month by subcutaneous injection. Regardless that it has the same safety and efficacy profile to other TNFi, golimumab is less effective than other TNFi in individuals who have unsuccessful a number of Organic treatment options. The authors thank the University https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/